scarring

Biotech

Acelyrin snags $250M, licenses Affibody IL-17 asset for 3 trials

Launched by ex-Horizon executives last December, Acelyrin now has $250 million to bankroll phase 2b studies of Affibody's inflammatory antibody.
Kyle LaHucik Nov 16, 2021 5:00am

'Safety concerns' see Biogen ax phase 2 study of fibrosis med

Sep 17, 2019 2:56am

AzurRx’s chronic pancreatitis drug hits the mark in phase 2

Sep 24, 2018 4:53pm

Early trial shows application of RXi’s skin-scar drug in wet AMD

Aug 1, 2018 2:42pm

Regenerating hair follicles could be key in reducing scar tissue

Jan 5, 2017 2:01pm

Noninvasive electroporation could forestall burn scars: Study

Aug 9, 2016 9:13am